A magnetic nanoparticle including a TRPV1 agonist, as well as methods of preparation and use, are described herein. A magnetically responsive pharmaceutical can include a core region having a magnetic nanoparticle (MNPs) and a TRPV1 protein agonist. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.

A magnetic nanoparticle including a TRPV1 agonist, as well as methods of preparation and use, are described herein. A magnetically responsive pharmaceutical can include a core region having a magnetic nanoparticle (MNPs) and a TRPV1 protein agonist. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.

Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.

In one aspect, methods and compositions are provided for treating a neoplasia such as a solid tumor, the methods and composition comprising a) a granulocyte colony-stimulating factor (G-CSF) compound; and b) a monoacetyl diacylglycerol compound such as 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG).

In one aspect, methods and compositions are provided for treating a neoplasia such as a solid tumor, the methods and composition comprising a) a granulocyte colony-stimulating factor (G-CSF) compound; and b) a monoacetyl diacylglycerol compound such as 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG).

In one aspect, methods and compositions are provided for treating a neoplasia such as a solid tumor, the methods and composition comprising a) a granulocyte colony-stimulating factor (G-CSF) compound; and b) a monoacetyl diacylglycerol compound such as 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG).

Method for minimizing exposure to a noxious substance, the method comprising the step of administering a spray composition to a surface or applying a wipe to a surface contaminated by the noxious substance, wherein the composition in the spray or impregnated into the wipe comprises a polyol fatty ester.

Method for minimizing exposure to a noxious substance, the method comprising the step of administering a spray composition to a surface or applying a wipe to a surface contaminated by the noxious substance, wherein the composition in the spray or impregnated into the wipe comprises a polyol fatty ester.

The present invention relates to a digestive lipase activity inhibitor containing, as an active ingredient, at least one selected from the group consisting of linoleic acid and oleic acid.

Some embodiments of the disclosure provide new uses of trans-1,3-dilinolein as medicaments and food. In an embodiment, an application of trans-1,3-dilinolein in the preparation of stomachic tonic and an application thereof include the preparation of medicaments for treating gastric cancer. Cell experiments show that trans-1,3-dilinolein promotes the proliferation of human gastric mucosal epithelial cell line GES-1 under normal oxygen and hypoxic conditions and it has concentration-dependent killing effect on human gastric cancer cell line HGC-27 and killing effect on hypoxic gastric cancer cells. At a concentration of 300 μm and more, trans-1,3-dilinolein kills gastric cancer cells significantly and the killing effect becomes more significant under hypoxic conditions.